Craniosynostosis, a condition where skull sutures fuse prematurely in children, can raise concerns about intracranial hypertension (ICH) – increased pressure within the skull. Traditionally, diagnosing ICH relies on invasive procedures. This review examines a promising new approach: handheld optical coherence tomography (OCT). Analyzing studies on handheld OCT use in children with craniosynostosis, we explore its feasibility, advantages, and potential role in improving diagnosis and patient care.
Craniosynostosis affects 1 in 2,000 newborns, often requiring surgery to correct skull shape and prevent complications. A significant concern is intracranial hypertension (ICH), which can damage the brain and vision if left untreated. Traditionally, diagnosing ICH involves invasive procedures like lumbar punctures or intracranial pressure monitoring. These methods are not ideal for young children, prompting the search for non-invasive alternatives.
Optical coherence tomography (OCT) is a revolutionary imaging technique that uses light to create detailed cross-sectional images of tissues. Recent advancements have led to the development of handheld OCT devices, making them more portable and user-friendly for pediatric applications. This review focuses on the feasibility of handheld OCT in diagnosing ICH in children with craniosynostosis.
Several studies have explored the use of handheld OCT in this context. These studies demonstrate promising results:
High Success Rates: Studies report successful image acquisition in a high percentage of children, exceeding 80% in some cases.
Feasibility for Young Children: Handheld OCT appears well-suited for young children, with good compliance and minimal discomfort.
Repeatability: Studies suggest good repeatability of OCT measurements, allowing for monitoring of pressure changes over time.
Handheld OCT offers several advantages over traditional methods for diagnosing ICH in children with craniosynostosis:
Non-invasive: Eliminates the need for needles or sedation, reducing risks and discomfort for children.
Quick and painless: OCT scans are completed in seconds, minimizing stress for patients.
Portable: Handheld devices allow for examinations at the bedside, improving accessibility.
Objective data: OCT provides quantitative measurements, aiding in diagnosis and monitoring.
While these initial studies are encouraging, further research is needed to fully establish handheld OCT as a standard diagnostic tool for ICH in children with craniosynostosis. Larger, multicenter trials are crucial to confirm its effectiveness and identify potential limitations. Additionally, exploring the correlation between OCT findings and other measures of ICH is important.
Handheld OCT holds immense potential for revolutionizing the diagnosis of ICH in children with craniosynostosis. This review highlights the feasibility, advantages, and future directions for this promising non-invasive technology. As research progresses, handheld OCT may become a valuable tool in improving early detection and management of ICH, leading to better outcomes for young patients.
1.
Le cancer et le COVID ont conduit le patient à une double transplantation de poumon.
2.
Effective for localizing small, non-palpable breast lesions is ultrasound-guided localization with magnetic seeds.
3.
Long-term study links chronic conditions in midlife to higher cancer risk and mortality
4.
Subcutaneous Cancer Immunotherapies Provide New Options for Physicians and Patients
5.
When does a melanoma metastasize? Implications for management
1.
Unlocking the Mysteries of Reticulocyte Counts: A Guide to Understanding Your Blood Results
2.
The Checkpoint Architect: Unraveling the Mechanisms of PD-L1 Regulation for the Next Generation of Small-Molecule Therapies
3.
Screening Efficacy, Molecular Precision, and Therapeutic Revolutions in Lung Cancer 2025
4.
Genetic Testing in Cancer Prevention: BRCA Mutations and Lynch Syndrome Unlocked
5.
Transforming Cancer Care: CAR T-Cell Therapy for Relapsed/Refractory NHL and ALL
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
An In-Depth Look At The Signs And Symptoms Of Lymphoma
4.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation